Study on the Treatment of CCD Combined With Cardiac Dysfunction With Yangxinshi Tablets

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

2,708

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
CCDCardiac Dysfunction
Interventions
DRUG

Yangxinshi tablet

"Basic treatment: All patients received a conventional treatment regimen, including outcome-improving drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEIs)) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Yangxinshi tablet, 3 tablets/3 times a day, taken orally"

DRUG

Blank control

"Basic treatment: All patients received a conventional treatment regimen, including prognosis-improving drugs (aspirin, β-blockers, statins, and ACEIs) and symptom-relieving drugs (nitrates, calcium antagonists, and diuretics).~Trial drug: Blank control"

Trial Locations (10)

110016

General Hospital of Northern Theater Command, Shenyang

110801

The First Hospital of China Medical University, Shenyang

116011

The First Affiliated Hospital of Dalian Medical University, Dalian

130022

The Second Norman Bethune Hospital of Jilin University, Changchun

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

230001

The First Affiliated Hospital of Ustc, Hefei

250012

Qilu Hospital of Shandong University, Jinan

310000

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

400042

Army Special Medical Center, Chongqing

050051

Hebei Provincial People's Hospital, Shijiazhuang

All Listed Sponsors
lead

SPH Qingdao Growful Pharmacetical Co.,Ltd

INDUSTRY